Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

St. Jude Children's Research Hospital16 enrolled

Overview

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Because they were excluded from most of the clinical trials of non-recombinant urate oxidase and rasburicase, the safety of rasburicase in this population is not known, though preliminary data indicates that the drug is safe. The primary objective of this study is to estimate the proportion of grade 3 or 4 allergic reactions to rasburicase in patients with a history of asthma or severe allergy (to antigens other than rasburicase or other urate oxidases) treated with rasburicase for the prevention or treatment of malignancy or chemotherapy-induced hyperuricemia. Patients at risk of tumor lysis syndrome with a history of asthma/atopy will be treated with rasburicase according to standard practice and observed for allergic reactions.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia Lymphoma Tumor Lysis Syndrome Hyperuricemia

Interventions

RasburicaseDRUG

Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * A diagnosis of hematologic malignancy. * Existing hyperuricemia or high risk of developing hyperuricemia of malignancy. * The treating clinician plans to treat the patient with rasburicase. A patient is only eligible for RASALL if the clinician has already decided to use rasburicase. Rasburicase should not be given in order to make a patient eligible for this non-therapeutic observational study. * No prior exposure to rasburicase or other urate oxidase. * A history of asthma or significant allergy. Exclusion Criteria * Wheezing or an active hypersensitivity reaction at entry. * Hypersensitivity to Aspergillus proteins.

Locations (11)

Stanford University

Palo Alto, California, United States

Rady Children's Hospital

San Diego, California, United States

Peyton Manning Children's Hospital at St. Vincent

Indianapolis, Indiana, United States

Outcomes

Primary Outcomes

Incidence of grade 3 or 4 allergic reactions

Time frame: Within 30 days of last treatment administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.